Artificial Intelligence in Photodynamic Therapy: From Molecular Design of Photosensitizers to Intelligent Delivery, Adaptive Dosimetry, and Personalized Prognostication of Results
4 affiliations
- 1Doctoral School, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland
- 2Department of Biochemistry and General Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-310 Rzeszów, Poland
- 3Department of Diagnostic Imaging and Nuclear Medicine, Faculty of Medicine, University of Rzeszów, 35-310 Rzeszów, Poland
- 4Department of Photomedicine and Physical Chemistry, Faculty of Medicine, Collegium Medicum, University of Rzeszów, 35-959 Rzeszów, Poland
Abstract
Photodynamic therapy (PDT) is a minimally invasive therapeutic approach based on the light-induced activation of a photosensitizer in the presence of molecular oxygen, resulting in the generation of reactive oxygen species, including singlet oxygen. Despite local selectivity and low systemic toxicity, reproducibility of PDT is restricted by non-uniform accumulation of the photosensitizer, aggregation and insufficient solubility of compounds, variability in the optical properties of tissues, hypoxia, oxygen consumption, photobleaching, and the lack of a universal measure of photodynamic dose. Artificial intelligence (AI), including machine learning and deep learning, graph neural networks, generative models, Bayesian optimization, and physics-informed neural networks, can integrate molecular, spectral, imaging, dosimetric, omics, and clinical data into decision-support systems. In this review, a closed AI–PDT cycle is considered, which includes the in silico design of photosensitizers, optimization of nanoformulations and delivery, personalized light exposure planning, real-time monitoring of photobleaching and oxygenation, and prediction of efficacy, toxicity, immune response, and long-term outcomes. Particular attention is given to data quality, external validation, interpretability, uncertainty assessment, and clinical readiness. This review emphasizes that the greatest potential of AI in PDT lies in its integration with mechanistic models of photochemistry, light transport, and oxygen dynamics, enabling the transition from empirical treatment protocols toward adaptive, reproducible, and personalized photomedicine. Unlike reviews focused on individual AI applications, this work considers the entire AI–PDT workflow as an interconnected system linking molecular design, drug delivery, dosimetry, treatment monitoring, and outcome prediction, while maintaining clinician oversight and the need for experimental and clinical validation.
Related
- Introducing 2-Thioxocoumarins as a New Class of Photosensitizers for Antimicrobial Photodynamic Therapy
- Phthalocyanine photosensitizers in antimicrobial photodynamic therapy as a multifunctional strategy for combating antimicrobial resistance.
- Artificial Intelligence in Neuroradiology: Transforming Diagnosis, Prognostication, and Workflow.
- Athlete-AI: a multi-modal artificial intelligence framework for personalized athlete monitoring and injury risk forecasting
- From digital reminders to artificial intelligence–enabled understanding: can personalized treatment predictions improve therapeutic adherence?
BibTeX
@article{marunych2026artificial,
title = {{Artificial Intelligence in Photodynamic Therapy: From Molecular Design of Photosensitizers to Intelligent Delivery, Adaptive Dosimetry, and Personalized Prognostication of Results}},
author = {Rostyslav Marunych and Dorota Bartusik-Aebisher and Klaudia Dynarowicz and Barbara Smolak and David Aebisher},
journal = {International journal of molecular sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198871},
url = {https://europepmc.org/article/PMC/PMC13665548},
note = {CC BY},
}
RIS
TY - JOUR
TI - Artificial Intelligence in Photodynamic Therapy: From Molecular Design of Photosensitizers to Intelligent Delivery, Adaptive Dosimetry, and Personalized Prognostication of Results
AU - Rostyslav Marunych
AU - Dorota Bartusik-Aebisher
AU - Klaudia Dynarowicz
AU - Barbara Smolak
AU - David Aebisher
PY - 2026
DA - 2026/10/01
JO - International journal of molecular sciences
DO - 10.3390/ijms27198871
UR - https://europepmc.org/article/PMC/PMC13665548
AB - Photodynamic therapy (PDT) is a minimally invasive therapeutic approach based on the light-induced activation of a photosensitizer in the presence of molecular oxygen, resulting in the generation of reactive oxygen species, including singlet oxygen. Despite local selectivity and low systemic toxicity, reproducibility of PDT is restricted by non-uniform accumulation of the photosensitizer, aggregation and insufficient solubility of compounds, variability in the optical properties of tissues, hypoxia, oxygen consumption, photobleaching, and the lack of a universal measure of photodynamic dose. Artificial intelligence (AI), including machine learning and deep learning, graph neural networks, generative models, Bayesian optimization, and physics-informed neural networks, can integrate molecular, spectral, imaging, dosimetric, omics, and clinical data into decision-support systems. In this review, a closed AI–PDT cycle is considered, which includes the in silico design of photosensitizers, optimization of nanoformulations and delivery, personalized light exposure planning, real-time monitoring of photobleaching and oxygenation, and prediction of efficacy, toxicity, immune response, and long-term outcomes. Particular attention is given to data quality, external validation, interpretability, uncertainty assessment, and clinical readiness. This review emphasizes that the greatest potential of AI in PDT lies in its integration with mechanistic models of photochemistry, light transport, and oxygen dynamics, enabling the transition from empirical treatment protocols toward adaptive, reproducible, and personalized photomedicine. Unlike reviews focused on individual AI applications, this work considers the entire AI–PDT workflow as an interconnected system linking molecular design, drug delivery, dosimetry, treatment monitoring, and outcome prediction, while maintaining clinician oversight and the need for experimental and clinical validation.
SN - 1422-0067
ER -